Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263. https://doi.org/10.3322/caac.21834

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024 [published correction appears in CA Cancer J Clin Mar-Apr;74(2):203]. CA Cancer J Clin 2024(74):12–49. https://doi.org/10.3322/caac.21820

Article  Google Scholar 

McAndrew NP, Finn RS (2022) Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract 18:319–327. https://doi.org/10.1200/OP.21.00384

Article  PubMed  Google Scholar 

Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ (2017) Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.12446.0.1111/ecc.12446

Article  PubMed  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135. https://doi.org/10.1056/NEJMoa1607427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091–1103. https://doi.org/10.1056/NEJMoa2107322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu W, Zhang J, Singh A, Kulkarni HR, Baum RP (2019) Metastatic nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor radionuclide therapy. Clin Nucl Med 44:989–990. https://doi.org/10.1097/RLU.0000000000002788

Article  PubMed  Google Scholar 

Emanuel O, Liu J, Schartinger VH, Nei WL, Chan YY, Tsang CM et al (2021) SSTR2 in nasopharyngeal carcinoma: relationship with latent EBV infection and potential as a therapeutic target. Cancers (Basel) 13:4944. https://doi.org/10.3390/cancers13194944

Article  CAS  PubMed  Google Scholar 

Gorin MA, Rowe SP (2017) Kidney cancer: PSMA: a potential therapeutic target in RCC. Nat Rev Urol 14:646–647. https://doi.org/10.1038/nrurol.2017.164

Article  CAS  PubMed  Google Scholar 

Zou Y, Tan H, Zhao Y, Zhou Y, Cao L (2019) Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett 17:1723–1731. https://doi.org/10.3892/ol.2018.9773

Article  CAS  PubMed  Google Scholar 

Dalm SU, Schrijver WA, Sieuwerts AM, Look MP, Ziel-van der Made AC, de Weerd V et al (2017) Prospects of targeting the gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer. PLoS One. https://doi.org/10.1371/journal.pone.0170536

Article  PubMed  PubMed Central  Google Scholar 

Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P et al (2005) Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 92:175–186. https://doi.org/10.1007/s10549-005-2414-0

Article  CAS  PubMed  Google Scholar 

Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA et al (2015) Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine C-X-C motif receptor 4 in breast cancer for imaging and therapy. J Nucl Med 56:1487–1493. https://doi.org/10.2967/jnumed.115.160739

Article  CAS  PubMed  Google Scholar 

Reubi C, Gugger M, Waser B (2002) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 29:855–862. https://doi.org/10.1007/s00259-002-0794-5

Article  CAS  PubMed  Google Scholar 

Dalm SU, Melis M, Emmering J, Kwekkeboom DJ, de Jong M (2016) Breast cancer imaging using radiolabelled somatostatin analogues. Nucl Med Biol 43:559–565. https://doi.org/10.1016/j.nucmedbio.2016.05.012

Article  CAS  PubMed  Google Scholar 

Nguyen A, Fullard K, Sheehan-Dare G, Tang R, Chan L, Ho B et al (2022) Diagnostic value of 68 Ga-DOTATATE PET-CT imaging for staging of ER+ /PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F-FDG PET-CT in a prospective pilot trial. J Med Imaging Radiat Oncol 66:731–737. https://doi.org/10.1111/1754-9485.13342

Article  PubMed  Google Scholar 

Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–151. https://doi.org/10.1148/radiographics.19.1.g99ja0761

Article  CAS  PubMed  Google Scholar 

Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516. https://doi.org/10.1148/rg.352140164

Article  PubMed  Google Scholar 

Hope TA, Calais J, Zhang L, Dieckmann W, Millo C (2019) 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on krenning scores and effect of tumor burden. J Nucl Med 60:1266–1269. https://doi.org/10.2967/jnumed.118.223016

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334. https://doi.org/10.1038/nrc3261

Article  CAS  PubMed  Google Scholar 

Turashvili G, Brogi E (2017) Tumor heterogeneity in breast cancer. Front Med (Lausanne) 4:227. https://doi.org/10.3389/fmed.2017.00227

Article  PubMed  Google Scholar 

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [published correction appears in J Clin Oncol. 2010 Jul 20;28(21):3543]. J Clin Oncol 28:2784–95. https://doi.org/10.1200/JCO.2009.25.6529

Article  PubMed  PubMed Central  Google Scholar 

Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C et al (2013) Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 18:667–674. https://doi.org/10.1634/theoncologist.2012-0350

Article  PubMed  PubMed Central  Google Scholar 

Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F et al (2021) Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer 7:41. https://doi.org/10.1038/s41523-021-00252-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G et al (2014) A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 50:277–289. https://doi.org/10.1016/j.ejca.2013.10.004

Article  CAS  PubMed  Google Scholar 

Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K et al (2016) Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol 27:480–487. https://doi.org/10.1093/annonc/mdv611

Article  CAS  PubMed  Google Scholar 

Ulaner GA, VanderMolen LA, Li G, Ferreira D (2024) Dotatate PET/CT and 225Ac-dotatate therapy for somatostatin receptor-expressing metastatic breast cancer. Radiology 312:e233408. https://doi.org/10.1148/radiol.233408

Article  PubMed  Google Scholar 

Armstrong N, Ryder S, Forbes C, Ross J, Quek RG (2019) A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543–561. https://doi.org/10.2147/CLEP.S206949

Article  PubMed